<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340455</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0907</org_study_id>
    <nct_id>NCT02340455</nct_id>
  </id_info>
  <brief_title>Effect of Oral Pregabalin on Hyperalgesia and Post-operative Pain in Patients Undergoing Nephrectomy Surgery: Sex Differential Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperalgesia is known to be caused by the excitatory amino acid through NMDA receptor. GABA,
      an inhibitory amino acid, alters the opioid receptor sensitivity against pain resulting
      hyperalgesia. If the GABA level can be maintained at certain level, the progression into
      hyperalgesia can be averted. GABA related drugs are known to decrease the postoperative
      opioid consumption, lower the degree of pain, and prevent hyperalgesia. We hypothesize the
      effective postoperative pain management and the prevention of hyperalgesia from pregabalin,
      GABA analogue, and the possible sex difference in such effects of pregabalin.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical threshold</measure>
    <time_frame>from 1 day before op to postop 48 hr</time_frame>
    <description>Mechanical threshold can be measured using von Frey filaments at both incision site and non-dominant arm</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Living Kidney Donors Undergoing VAMS-nephrectomy</condition>
  <arm_group>
    <arm_group_label>Pregabalin_male</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin_female</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo_male</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo_female</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin_male</intervention_name>
    <description>Pregabalin 150mg bid 1day Men</description>
    <arm_group_label>Pregabalin_male</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin_female</intervention_name>
    <description>Pregabalin 150mg bid 1day Women</description>
    <arm_group_label>Pregabalin_female</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo_Men</intervention_name>
    <description>Placebo durg</description>
    <arm_group_label>Placebo_male</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo_Women</intervention_name>
    <description>Placebo_Women</description>
    <arm_group_label>Placebo_female</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18, &lt;51 years

               -  healthy patients accepted for video-assisted living donor nephrectomy

        Exclusion Criteria:

          -  Female patients who are pregnant or menopause

          -  Patients undergoing hormonal therapy

          -  Patients having neurologic disease or already taking GABA related drugs (pregabalin,
             gabapentin), or taking opioid drugs

          -  Insulin resistant diabetes

          -  Renal deficiency (eGFR &lt; 60 ml/min/1.73 m2)

          -  Emergency operation, hemodynamically unstable patients

          -  Foreigner

          -  allergic to medication given in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bon-Nyeo Koo, MD</last_name>
    <phone>+82-2-2228-2420</phone>
    <email>koobn@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon-Nyeo Koo, Ph.D.</last_name>
      <phone>82-10-9982-4469</phone>
      <email>koobn@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

